Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer

Roberto Ruiz-Cordero; Walter Patrick Devine

doi:10.1016/j.path.2019.11.002

journal article Mar 01, 2020

Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer

Roberto Ruiz-Cordero Walter Patrick Devine

Surgical Pathology Clinics Vol. 13 No. 1 pp. 17-33 · Elsevier BV

View at Publisher Save 10.1016/j.path.2019.11.002

Topics

No keywords indexed for this article. Browse by subject →

References

100

[1]

Adler (1912)

[2]

One Hundred Years of Lung Cancer

Stephen G. Spiro, Gerard A. Silvestri

American Review of Respiratory Disease 2005 10.1164/rccm.200504-531oe

[3]

Siegel "Cancer statistics, 2019" CA Cancer J Clin (2019)

[4]

Lee "Chemotherapy for lung cancer in the era of personalized medicine" Tuberc Respir Dis (Seoul) (2019) 10.4046/trd.2018.0068

[5]

Gridelli "Non-small-cell lung cancer" Nat Rev Dis Primers (2015) 10.1038/nrdp.2015.9

[6]

Haddadin "History of small-cell lung cancer" Clin Lung Cancer (2011) 10.1016/j.cllc.2011.03.002

[7]

Swanton "Clinical implications of genomic discoveries in lung cancer" N Engl J Med (2016) 10.1056/nejmra1504688

[8]

Relli "Abandoning the notion of non-small cell lung cancer" Trends Mol Med (2019) 10.1016/j.molmed.2019.04.012

[9]

Brainard "The diagnosis of non-small cell lung cancer in the molecular era" Mod Pathol (2019) 10.1038/s41379-018-0156-x

[10]

Borczuk "Uncommon types of lung carcinoma with mixed histology: sarcomatoid carcinoma, adenosquamous carcinoma, and mucoepidermoid carcinoma" Arch Pathol Lab Med (2018) 10.5858/arpa.2017-0584-ra

[11]

The biology and management of non-small cell lung cancer

Roy S. Herbst, Daniel Morgensztern, Chris Boshoff

Nature 2018 10.1038/nature25183

[12]

Comprehensive molecular profiling of lung adenocarcinoma

Nature 2014 10.1038/nature13385

[13]

Kim "Identification of bronchioalveolar stem cells in normal lung and lung cancer" Cell (2005) 10.1016/j.cell.2005.03.032

[14]

Skoulidis "Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy" Nat Rev Cancer (2019) 10.1038/s41568-019-0179-8

[15]

Paez "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy" Science (2004) 10.1126/science.1099314

[16]

Endoh "Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction" J Clin Oncol (2004) 10.1200/jco.2004.04.109

[17]

Gordon "A prognostic test for adenocarcinoma of the lung from gene expression profiling data" Cancer Epidemiol Biomarkers Prev (2003)

[18]

Hayes "Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts" J Clin Oncol (2006) 10.1200/jco.2005.05.1748

[19]

Parmigiani "A cross-study comparison of gene expression studies for the molecular classification of lung cancer" Clin Cancer Res (2004) 10.1158/1078-0432.ccr-03-0490

[20]

Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways

Ping Wee, Zhixiang Wang

Cancers 2017 10.3390/cancers9050052

[21]

Ullrich "Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells" Nature (1984) 10.1038/309418a0

[22]

Kumar "Structure and clinical relevance of the epidermal growth factor receptor in human cancer" J Clin Oncol (2008) 10.1200/jco.2007.12.1178

[23]

Lee "Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain" PLoS Med (2006) 10.1371/journal.pmed.0030485

[24]

Red Brewer "Mechanism for activation of mutated epidermal growth factor receptors in lung cancer" Proc Natl Acad Sci U S A (2013) 10.1073/pnas.1220050110

[25]

An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor

Xuewu Zhang, Jodi Gureasko, Kui Shen et al.

Cell 2006 10.1016/j.cell.2006.05.013

[26]

Barber "Somatic mutations of EGFR in colorectal cancers and glioblastomas" N Engl J Med (2004) 10.1056/nejm200412303512724

[27]

Gullick "Expression of epidermal growth factor receptors on human cervical, ovarian, and vulval carcinomas" Cancer Res (1986)

[28]

Carey "Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib" Cancer Res (2006) 10.1158/0008-5472.can-06-0453

[29]

Fujino "A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer" Eur J Cancer (1996) 10.1016/s0959-8049(96)00243-2

[30]

Pennell "SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer" J Clin Oncol (2019) 10.1200/jco.18.00131

[31]

Oberndorfer "Molecular pathology of lung cancer: current status and perspectives" Curr Opin Oncol (2018) 10.1097/cco.0000000000000429

[32]

Piotrowska "Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET fusion" Cancer Discov (2018) 10.1158/2159-8290.cd-18-1022

[33]

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S Thress, Cloud P Paweletz, Enriqueta Felip et al.

Nature Medicine 2015 10.1038/nm.3854

[34]

Niederst "The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies" Clin Cancer Res (2015) 10.1158/1078-0432.ccr-15-0560

[35]

Borczuk "Keeping up with testing guidelines in lung cancer" Arch Pathol Lab Med (2018) 10.5858/arpa.2018-0110-ed

[36]

Lindeman Arch Pathol Lab Med (2018) 10.5858/arpa.2017-0388-cp

[37]

Bayliss "Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs" Cell Mol Life Sci (2016) 10.1007/s00018-015-2117-6

[38]

Pan "ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features" Lung Cancer (2014) 10.1016/j.lungcan.2014.02.007

[39]

Rosenbaum "Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer" Mod Pathol (2018) 10.1038/modpathol.2017.181

[40]

Stumpfova "Zeroing in on ROS1 rearrangements in non-small cell lung cancer" Clin Cancer Res (2012) 10.1158/1078-0432.ccr-12-1812

[41]

Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations

Alexander Drilon, Sai-Hong Ignatius Ou, Byoung Chul Cho et al.

Cancer Discovery 2018 10.1158/2159-8290.cd-18-0484

[42]

Sheikine "BRAF in lung cancers: analysis of patient cases reveals recurrent BRAF mutations, fusions, kinase duplications, and concurrent alterations" JCO Precis Oncol (2018) 10.1200/po.17.00172

[43]

Suh "Comprehensive genomic profiling facilitates implementation of the national comprehensive cancer network guidelines for lung cancer biomarker testing and identifies patients who may benefit from enrollment in mechanism-driven clinical trials" Oncologist (2016) 10.1634/theoncologist.2016-0030

[44]

Chen "BRAF mutations in patients with non-small cell lung cancer: a systematic review and meta-analysis" PLoS One (2014) 10.1371/journal.pone.0101354

[45]

Schmid "Overcoming resistance in a BRAF V600E-mutant adenocarcinoma of the lung" Curr Oncol (2018) 10.3747/co.25.3936

[46]

Khunger "Dabrafenib in combination with trametinib in the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer: clinical evidence and experience" Ther Adv Respir Dis (2018) 10.1177/1753466618767611

[47]

Piva "Across the universe of K-RAS mutations in non-small-cell-lung cancer" Curr Pharm Des (2014) 10.2174/13816128113196660761

[48]

Ferrer "KRAS-Mutant non-small cell lung cancer: from biology to therapy" Lung Cancer (2018) 10.1016/j.lungcan.2018.07.013

[49]

Matikas "Targeting KRAS mutated non-small cell lung cancer: a history of failures and a future of hope for a diverse entity" Crit Rev Oncol Hematol (2017) 10.1016/j.critrevonc.2016.12.005

[50]

Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma

Gregory J. Riely, Mark G. Kris, Daniel Rosenbaum et al.

Clinical Cancer Research 2008 10.1158/1078-0432.ccr-08-0646

Showing 50 of 100 references

Cited By

399

Pixel-Level Classification of Five Histologic Patterns of Lung Adenocarcinoma

Dan Shao, Fei Su · 2023

Analytical Chemistry

Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma

Dongxiao Ding, Liangbin Wang · 2023

Translational Oncology

Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma

Yingfeng Jiang, Lili Yu · 2023

Molecular Immunology

LncRNA CCDC144NL-AS1 Serves as a Prognosis Biomarker for Non-small Cell Lung Cancer and Promotes Cellular Function by Targeting miR-490-3p

Lei Zhang, Baihong Chi · 2021

Molecular Biotechnology

Metrics

399

Citations

100

References

Details

Published: Mar 01, 2020
Vol/Issue: 13(1)
Pages: 17-33
License: View

Authors

R

Roberto Ruiz-Cordero

W

Walter Patrick Devine

Cite This Article

Roberto Ruiz-Cordero, Walter Patrick Devine (2020). Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer. Surgical Pathology Clinics, 13(1), 17-33. https://doi.org/10.1016/j.path.2019.11.002

Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer

You May Also Like